Current Progress and Future Developments of Antibody Drug Conjugates 
in Lung Cancer

Abstract

Antibody drug conjugates (ADCs) are a novel class of anti-cancer drugs, which combined the specificity of monoclonal antibodies with the cytotoxic palyload via the linkers. Many ADCs have not only verified impressive activity in a variety of cancers, including breast cancer and hematological system tumors, but also in lung cancer. The aim of this study was to provide informations for practice by summarizing the mechanism of action, clinical application and problems and challenges of ADCs.

Keywords

• lung neoplasms
• antibody drug conjugates (adcs)
• precision medicine